In today's ACT Brief, we examine how AI enables sponsors to pressure-test protocols before enrollment, HHS's multi-initiative effort to accelerate trial design and execution, and FDA approval expanding heart disease therapy to adolescents.
News|Podcasts|February 23, 2026
ACT Brief: Evinova Expands AI Partnerships, CTPM Role Evolves, and FDA Pressure Builds on GLP-1 Market
Author(s)Andy Studna, Senior Editor
In today’s ACT Brief, we examine how Evinova is scaling AI-driven clinical development through industry collaboration, how the clinical trial project manager role is evolving amid growing complexity, and how FDA scrutiny of compounded GLP-1s could reshape market dynamics.
This is the Applied Clinical Trials Brief—your fast track to the latest insights shaping clinical operations and drug development.
- Evinova has entered a new phase of growth through strategic
collaborations with AstraZeneca, Astellas Pharma, and Bristol Myers Squibb aimed at scaling its AI-native platform across global development. The model centers on opt-in data sharing to generate benchmarks and improve trial execution, with early deployments already showing measurable reductions in study costs driven by more efficient protocol design and fewer downstream amendments. - A new contributor
analysis on ACT highlights how the clinical trial project manager role is expanding as digital tools, regulatory shifts, and operational complexity reshape trial execution. Leaders are now expected to combine traditional project oversight with technical fluency and adaptive decision-making, as organizations place greater emphasis on real-time data, distributed teams, and continuous change management to maintain timelines and performance. - In a new video
interview on Pharm Exec, Jay Bregman, CEO and co-founder of Andel, warned that increased scrutiny from the FDA on non-approved GLP-1 products could significantly disrupt the obesity and diabetes market. The expected crackdown on compounded therapies may force patients to seek alternative access pathways, while also reinforcing incentives for manufacturers to prioritize fully approved, regulated treatments.
That’s all for today’s ACT Brief. Join us tomorrow for more updates shaping clinical operations and drug development. Thanks for listening.
Related to this article
In today's ACT Brief, we examine AI's role as trial design advisor with human leadership, how to govern autonomous agents in regulated operations, and real-world outcomes from switching to oral weight-loss therapy.
In today's ACT Brief, we examine how data drives honest enrollment assumptions, why RWE infrastructure lags ambition, and the disconnect between FDA rulemaking and enforcement on compounded therapies.
In today's ACT Brief, we examine what AI simulations surface in trial design, how RBQM delivers measurable financial returns, and three new FDA-approved treatments across hair loss, movement disorder, and bone disease.
In today's ACT Brief, we examine how AI is surfacing endpoint options beyond traditional design thinking, why sponsor oversight of outsourced work often fails on inspection despite being robust in practice, and a new combination drug for advanced kidney cancer.
In today's ACT Brief, we examine what patient-site relationships need beyond easier technology, how to build defensible rare disease evidence from scratch, and how real-world data and AI improve enrollment screening accuracy.
In today's ACT Brief, we examine why defensible trial data depends on traceability and platform ownership, what CGT site readiness requires as therapy moves to community care, and why data harmonization is AI's primary bottleneck.
In this episode of Beyond Compliance, Otis Johnson, PhD, MPA, founder and principal consultant at Vantix Operations, speaks with Cecilia Xi, PhD, VP of clinical and scientific affairs at Vivalink, about why defensible trial data depends on traceability, platform ownership, and device strategy long after a study ends.
Trending on Applied Clinical Trials Online
1
The Control Plane for Agentic Clinical Operations: Governing Autonomous Digital Actors in Regulated Trials
2
Hierarchical Endpoints in Cardiology: How Much Treatment Benefit, and From Where
3
HHS Launches SURPASS Program and Three Complementary Initiatives to Transform Clinical Trial Design and Infrastructure
4
What ClinOps Professionals Just Starting With AI Should Keep Top of Mind
5